These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30977429)

  • 1. Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer.
    Xie F; Chen R; Zhang L; Yin Z; Zhu Q; You S; Jiang C; Li Y; Li S; Zha X; Wang J
    Nanomedicine (Lond); 2019 Jun; 14(12):1595-1603. PubMed ID: 30977429
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study.
    Shizuku M; Shibata M; Shimizu Y; Takeuchi D; Mizuno Y
    Nagoya J Med Sci; 2020 Aug; 82(3):457-467. PubMed ID: 33132430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
    Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K
    Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.
    Tokunaga S; Takashima T; Kashiwagi S; Noda S; Kawajiri H; Tokumoto M; Nishimura S; Nishimori T; Ikeda K; Ogawa Y; Mizuyama Y; Sunami T; Tezuka K; Yamagata S; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2019 Apr; 39(4):2053-2059. PubMed ID: 30952749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study.
    Seki H; Higeta K; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Clin Breast Cancer; 2022 Apr; 22(3):235-243. PubMed ID: 34289949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
    Gluz O; Kuemmel S; Nitz U; Braun M; Lüdtke-Heckenkamp K; von Schumann R; Darsow M; Forstbauer H; Potenberg J; Uleer C; Grischke EM; Aktas B; Schumacher C; Zu Eulenburg C; Kates R; Jóźwiak K; Graeser M; Wuerstlein R; Baehner R; Christgen M; Kreipe HH; Harbeck N
    Ann Oncol; 2023 Jun; 34(6):531-542. PubMed ID: 37062416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
    Shi W; Wan X; Wang Y; He J; Huang X; Xu Y; Zhang W; Chen R; Wang L; Zheng R; Ma L; Li X; Xu L; Zha X; Wang J
    Nanomedicine; 2023 Apr; 49():102666. PubMed ID: 36889422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
    Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
    Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
    Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
    Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer.
    Li Y; Chen X; Zhu Q; Chen R; Xu L; Li S; Shi X; Xu H; Xu Y; Zhang W; Huang X; Zha X; Wang J
    Nanomedicine (Lond); 2021 Feb; 16(5):391-400. PubMed ID: 33502252
    [No Abstract]   [Full Text] [Related]  

  • 13. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer.
    Matsumoto A; Jinno H; Naruse S; Isono Y; Maeda Y; Sato A; Yamada M; Ikeda T; Sasajima Y
    Jpn J Clin Oncol; 2023 Dec; 53(12):1119-1124. PubMed ID: 37609671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
    Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
    Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.
    Zhang W; Xu Y; Shi X; Huang X; Chen R; Xu H; Shi W; Wan X; Wang Y; He J; Li C; Wang J; Zha X
    Nanomedicine (Lond); 2022 Apr; 17(10):683-694. PubMed ID: 35393861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Futamura M; Oba M; Masuda N; Bando H; Okada M; Yamamoto Y; Kin T; Saeki T; Nagashima T; Kuwayama T; Toh U; Hirano A; Inokuchi M; Yamagami K; Mizuno Y; Kojima Y; Nakayama T; Yasojima H; Ohno S
    Breast Cancer; 2021 Sep; 28(5):1023-1037. PubMed ID: 33811599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    Liu M; Liu S; Yang L; Wang S
    BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
    Futamura M; Ishihara K; Nagao Y; Ogiso A; Niwa Y; Nakada T; Kawaguchi Y; Ikawa A; Kumazawa I; Mori R; Kitazawa M; Hosono Y; Kuno M; Kawajiri M; Nakakami A; Takeuchi M; Morikawa A; Tokumaru Y; Katagiri Y; Asano Y; Mushika Y; Shimokawa T; Matsuhasih N
    Breast Cancer; 2023 Mar; 30(2):293-301. PubMed ID: 36609911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
    Zong Y; Wu J; Shen K
    Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.